Development of ALG-097431 as a broad-spectrum 3CL pro inhibitor
开发 ALG-097431 作为广谱 3CL 前体抑制剂
基本信息
- 批准号:10513921
- 负责人:
- 金额:$ 422.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVA549ACE2AdultAirAnimalsAntiviral AgentsAntiviral TherapyAppearanceBelgiumBindingBiochemicalBiological AssayBiological AvailabilityCD3 AntigensCanis familiarisCardiovascular systemCaspaseCellsChemistryClinical ResearchClinical TrialsCoronavirusCrystallizationDevelopmentDoseDrug DesignEnzymesEpithelial CellsExcretory functionExhibitsFormulationGoalsHIV InfectionsHamstersHepatitis CHepatitis C TherapyHomologous GeneHumanIn VitroInfectionInstitutesIon ChannelIonsLiquid substanceLungMetabolismMethodsModelingMonitorNeuraxisOralPeptide HydrolasesPharmaceutical PreparationsPharmacologic SubstancePharmacologyPharmacology StudyPhosphotransferasesPhototoxicityProcessPropertyRNARattusRegulationRespiratory SystemRitonavirSARS-CoV-2 B.1.1.7SARS-CoV-2 infectionSafetySeriesSolubilitySprague-Dawley RatsStructureSystemTherapeuticToxic effectToxicologyValidationViralVirusabsorptionairway epitheliumbasebetacoronaviruschemical propertychymotrypsincytotoxicitydrug discoverydrug synthesisenantiomergenotoxicitygood laboratory practicehuman coronavirusimprovedin vivoindexinginhibitormetropolitannanomolarpharmacokinetics and pharmacodynamicsphysical propertyprogramsreceptorsafety assessmentsafety studyscale upscreening panelsmall moleculethree dimensional cell cultureviral RNA
项目摘要
Project Summary/Abstract: Development of ALG-097431 as a Broad-Spectrum SARS-CoV-2 3CLpro
Inhibitor
Inhibition of viral proteases with small molecule drugs is a proven successful therapeutic approach and is
currently used for the treatment of HCV and HIV infection. The SARS-CoV-2 main, 3-chymotrypsin-like cysteine
protease (Mpro, 3CLpro) represents another promising viral protease target for antiviral therapy with no human
homolog. The discovery and development of small molecule, covalent binding inhibitors of the 3CLpro is the
focus of this program. Together with our collaborators at the Centre for Drug Design and Discovery (CD3) and
the Rega Institute at KU Leuven, Belgium, we have developed multiple biochemical and cell-based assays to
profile compounds and have access to the hamster model of SARS-CoV-2 infection. Through structure-based
optimization, combined with selectivity and SARS-CoV-2 3CLpro biochemical enzymatic assays, we have
identified a series of highly selective and potent 3CLpro inhibitors. The inhibition of replication of SARS-CoV-2
by these compounds was confirmed in A549 cells expressing the human ACE-2 receptor with compounds
demonstrating low nanomolar EC50 values. No cytotoxicity was observed in A549 cells at concentrations up to
100 μM. The activity of these compounds extended to other human coronaviruses such as the alpha-coronavirus
229E and the beta-coronavirus OC43, demonstrating broad-spectrum anti-coronaviral activity. A representative
compound, ALG-097111, was taken into an in vivo efficacy model in which hamsters were challenged with
SARS-CoV-2. At two days post-infection, a robust and significant 3.5 log10 (RNA copies/mg) reduction of the
viral RNA copies and 3.7 log10 (TCID50/mg) reduction in the infectious virus titers in the lungs was observed in
ALG-097111-treated animals. Further compound optimization has resulted in the development of ALG-097431.
This compound demonstrates an IC50 of 4 nM vs. the 3CLpro enzyme and an EC50 of 39 nM (selectivity index of
>1200) in a A549-ACE2/B.1.1.7 cell-based assay. Further, ALG-097431 exhibits potent activity in a primary
human airway epithelial cell, air-liquid interface 3D-culture system (EC90 = 12 nM). The compound demonstrates
a clean in vitro ADME-tox profile and shows good oral bioavailability in rats and dogs. Human efficacious dose-
projections indicate the potential for twice-daily dosing with a 250 – 600 mg dose without the need for co-
administration with ritonavir. The goals of this project are to advance ALG-097431 into human clinical trials while
simultaneously optimizing further compounds for enhanced antiviral activity and PK properties. Initially this will
involve establishing PK/PD correlations and conducting further selectivity analysis and more extensive PK
analysis. Following exploratory safety pharmacology studies, GMP drug synthesis, formulation development and
validation of bioanalytical methods will be initiated. Prior to the initiation of clinical studies, the potential toxicity
of ALG-097431 will be evaluated in multiple in vitro and in vivo studies conducted under GLP regulations.
项目摘要/摘要:ALG-097431作为广谱SARS-CoV-2 3CLpro的开发
抑制剂
用小分子药物抑制病毒蛋白酶是一种经证实成功的治疗方法,
目前用于治疗HCV和HIV感染。SARS-CoV-2主要的3-糜蛋白酶样半胱氨酸
蛋白酶(Mpro,3CLpro)代表了另一种有前途的病毒蛋白酶靶点,用于抗病毒治疗,而不需要人
同源物3CLpro的小分子、共价结合抑制剂的发现和开发是本领域的一个热点。
这个节目的焦点。与我们在药物设计和发现中心(CD 3)的合作者一起,
在比利时鲁汶大学的Rega研究所,我们已经开发了多种生物化学和基于细胞的检测方法,
分析化合物并获得SARS-CoV-2感染的仓鼠模型。通过基于结构的
优化,结合选择性和SARS-CoV-2 3CLpro生化酶法,我们有
鉴定了一系列高选择性和有效的3CLpro抑制剂。SARS-CoV-2复制的抑制
在表达人ACE-2受体的A549细胞中证实了这些化合物与化合物
表明低纳摩尔EC 50值。在A549细胞中,在高达
100 μM。这些化合物的活性扩展到其他人类冠状病毒,如α-冠状病毒
229 E和β-冠状病毒OC 43,表现出广谱抗冠状病毒活性。一名代表
将化合物ALG-097111引入体内功效模型,其中仓鼠用
SARS-CoV-2.在感染后两天,在感染后24小时,
病毒RNA拷贝和3.7 log 10(TCID 50/mg)的下降,在肺中的感染性病毒滴度观察到,
ALG-097111给药动物。进一步的化合物优化导致ALG-097431的开发。
该化合物相对于3CLpro酶显示出4 nM的IC 50和39 nM的EC 50(选择性指数为1.5 nM)。
>1200)。此外,ALG-097431在原发性肿瘤中表现出强效活性。
人气道上皮细胞,气液界面三维培养系统(EC 90 = 12 nM)。该化合物证明
清洁的体外ADME-毒性特征,并在大鼠和犬中显示出良好的口服生物利用度。人体有效剂量-
预测表明,每天两次给药的潜力与250 - 600毫克剂量,而不需要共同的,
利托那韦的给药。该项目的目标是将ALG-097431推进到人体临床试验中,
同时优化其它化合物以增强抗病毒活性和PK性质。最初,这将
包括建立PK/PD相关性,并进行进一步的选择性分析和更广泛的PK
分析.在探索性安全药理学研究、GMP药物合成、制剂开发和
将启动生物分析方法的验证。在临床研究开始之前,
将在根据GLP法规进行的多项体外和体内研究中评价ALG-097431。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julian A Symons其他文献
Julian A Symons的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
- 批准号:22007020
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
- 批准号:81473017
- 批准年份:2014
- 资助金额:66.0 万元
- 项目类别:面上项目
用于识别癌细胞A549的磁共振和荧光双功能探针的研究
- 批准号:21305156
- 批准年份:2013
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
DNA甲基化参与非小细胞肺癌细胞(A549/DDP)顺铂耐药的研究
- 批准号:81101650
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
白藜芦醇诱导人肺癌A549细胞PML蛋白自噬性降解的机制研究
- 批准号:81172089
- 批准年份:2011
- 资助金额:55.0 万元
- 项目类别:面上项目
Id3在肺腺癌中的表达分析及其对A549肺腺癌细胞增殖影响的机制研究
- 批准号:81171652
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
hTERT启动子调控下CD137L在肺癌A549细胞中的表达及其抑制肿瘤免疫的实验研究
- 批准号:81172140
- 批准年份:2011
- 资助金额:64.0 万元
- 项目类别:面上项目
姜黄素调控肺腺癌A549细胞株SP细胞Wnt信号通路的研究
- 批准号:81001578
- 批准年份:2010
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
PTEN抑制A549肺癌细胞趋电性及调控直流电场对肺癌转移诱导的研究
- 批准号:81000938
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Toxicity evaluation and mechanism of acid gas generation from halogen fire extinguisher by combination of FTIR analysis and human cell A549 viability
结合 FTIR 分析和人体细胞 A549 活力评价卤素灭火器产生酸性气体的毒性和机制
- 批准号:
26350465 - 财政年份:2014
- 资助金额:
$ 422.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An in vitro system has identified a factor released only by Pseudomonas aeruginosa biofilm and not planktonic bacteria that interacts with A549 lung epithelia and LL-37 pre-treatment of biofilms minimizes its effects.
体外系统已鉴定出仅由铜绿假单胞菌生物膜而不是浮游细菌释放的与 A549 肺上皮细胞相互作用的因子,并且生物膜的 LL-37 预处理可最大限度地减少其影响。
- 批准号:
263429 - 财政年份:2012
- 资助金额:
$ 422.8万 - 项目类别:
Mechanism for the release of IL-8 from A549 cells treated with alpha-toxin.
用 α 毒素处理的 A549 细胞释放 IL-8 的机制。
- 批准号:
21790431 - 财政年份:2009
- 资助金额:
$ 422.8万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Transcriptional regulation mechanisms of arylhydrocarbon receptor(AhR), Arnt and E2F genes on proliferation process in A549 cells as promoter activity in carcinogenesis by dioxin
芳基烃受体(AhR)、Arnt和E2F基因对A549细胞增殖过程的转录调控机制作为二恶英致癌的促进剂活性
- 批准号:
19590127 - 财政年份:2007
- 资助金额:
$ 422.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Transcriptional regulation of arylhydrocarbon receptor (AhR), Arnt and E2F genes on proliferation process in A549 cells by dioxin and its mechanism.
二恶英对芳烃受体(AhR)、Arnt和E2F基因转录调控A549细胞增殖过程及其机制
- 批准号:
17590109 - 财政年份:2005
- 资助金额:
$ 422.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)